173 related articles for article (PubMed ID: 8540713)
1. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD
Antimicrob Agents Chemother; 1995 Sep; 39(9):2042-7. PubMed ID: 8540713
[TBL] [Abstract][Full Text] [Related]
2. The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD
Chemotherapy; 1999 Jun; 45 Suppl 1():48-53. PubMed ID: 10394021
[TBL] [Abstract][Full Text] [Related]
3. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
Noskin G; Pietrelli L; Gurwith M; Bowden R
Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
5. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
Azanza Perea JR; Barberán J
Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.
Bowden RA; Cays M; Gooley T; Mamelok RD; van Burik JA
J Infect Dis; 1996 May; 173(5):1208-15. PubMed ID: 8627074
[TBL] [Abstract][Full Text] [Related]
7. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.
Gubbins PO; Penzak SR; Polston S; McConnell SA; Anaissie E
Pharmacotherapy; 2002 Aug; 22(8):961-71. PubMed ID: 12173799
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
Ohata Y; Tomita Y; Suzuki K; Maniwa T; Yano Y; Sunakawa K
Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
[TBL] [Abstract][Full Text] [Related]
9. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion.
Anaissie EJ; Mattiuzzi GN; Miller CB; Noskin GA; Gurwith MJ; Mamelok RD; Pietrelli LA
Antimicrob Agents Chemother; 1998 Mar; 42(3):606-11. PubMed ID: 9517940
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
12. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
14. Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
Krüger W; Stockschläder M; Rüssmann B; Berger C; Hoffknecht M; Sobottka I; Kohlschütter B; Kroschke G; Kröger N; Horstmann M
Br J Haematol; 1995 Nov; 91(3):684-90. PubMed ID: 8555076
[TBL] [Abstract][Full Text] [Related]
15. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
16. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients.
Camp MJ; Wingard JR; Gilmore CE; Lin LS; Dix SP; Davidson TG; Geller RB
Antimicrob Agents Chemother; 1998 Dec; 42(12):3103-6. PubMed ID: 9835498
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Manzoni P; Galletto P; Rizzollo S; Franco C; Gallo E; Antonucci R; Fanos V; Farina D
Early Hum Dev; 2012 May; 88 Suppl 2():S86-91. PubMed ID: 22633524
[TBL] [Abstract][Full Text] [Related]
19. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
20. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
